Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Shares Shorted: Short Interest Down 50.4% in September

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant decrease in short interest in September. As of September 15th, there was short interest totaling 131,482 shares, a decrease of 50.4% from the August 31st total of 265,115 shares. Based on an average daily volume of 4,781,987 shares, the short-interest ratio is presently 0.0 days. Approximately 3.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BJDX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, September 21st. Wall Street Zen cut Bluejay Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, September 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Insider Activity at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider directly owned 92,055 shares in the company, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is owned by corporate insiders.

Bluejay Diagnostics Trading Up 0.0%

BJDX traded up $0.00 during midday trading on Tuesday, hitting $0.96. The company’s stock had a trading volume of 86,258 shares, compared to its average volume of 2,451,344. Bluejay Diagnostics has a 52-week low of $0.80 and a 52-week high of $16.68. The firm has a 50-day moving average price of $0.96 and a two-hundred day moving average price of $1.83. The firm has a market cap of $4.29 million, a P/E ratio of -0.14 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX) last released its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc is a medical technology company developing rapid, near-patient diagnostic solutions for use in hospitals and other care settings. The company’s focus is on helping clinicians obtain actionable information from small blood samples without relying exclusively on centralized laboratory testing.

Its primary product platform, the Symphony System, combines a reusable analyzer with disposable test cartridges designed to analyze whole-blood biomarkers. The platform’s initial focus has been the Symphony IL-6 Test, which measures interleukin-6, an inflammatory biomarker associated with immune-system activation and conditions such as sepsis.